Elevance Health and UnitedHealth Group rank among the largest publicly traded managed-care organizations in the United States, so this comparison matters for investors tracking the health-insurance sector. Both have worked through a challenging stretch marked by elevated medical utilization, policy changes, and regulatory pressure, yet their trajectories have begun to differ in meaningful ways. Long-term investors looking for steady compounders and traders monitoring relative performance can both gain from understanding how these bellwethers vary in business mix, growth drivers, and market positioning. The analysis that follows looks at recent results and observable trends to clarify how ELV and UNH compare at present. I also checked this using Tickeron’s AI Screener to see how the stocks line up against peers.
Elevance Health, which rebranded from Anthem in 2022, runs a diversified health-benefits operation across commercial, Medicaid, Medicare, and individual plans, together with its Carelon services business that includes pharmacy benefit management, behavioral health, and care delivery. In recent weeks, the company reported third-quarter results that exceeded consensus, with adjusted EPS of $6.99 versus roughly $4.70 expected and operating revenue near $50.4 billion. Management raised its full-year 2026 adjusted EPS guidance to at least $29.00 and improved its operating cash-flow outlook.
The quarter featured a 70-basis-point improvement in the benefit expense ratio to 90.6%, supported by stronger Medicare Advantage and individual-market results. Medical membership fell by about 487,000 year over year to roughly 44.9 million, reflecting a deliberate shift in positioning. Carelon helped diversify outcomes, with operating revenue rising 5% and operating gain advancing 17%. Analyst price-target increases have helped sentiment, although part of the earnings beat came from non-operating items, which tempered the market reaction.
UnitedHealth Group is the largest U.S. health insurer and a diversified healthcare enterprise that pairs its UnitedHealthcare insurance segment with the Optum platform covering Optum Health, Optum Rx, and Optum Insight. In recent weeks, the company reported third-quarter adjusted EPS of $4.69, well above the roughly $4.12–$4.14 consensus, on revenue of about $112.7 billion. It raised full-year 2026 adjusted EPS guidance to at least $20.50, marking the third increase this year.
The clearest development was margin recovery: the medical care ratio improved to 88.4% from 89.9% a year earlier, aided in part by favorable prior-period reserve development. Membership declined to about 48.3 million from 50.1 million as the firm intentionally exited unprofitable markets and plans. Optum Health showed a sharp swing, with operating earnings rising to roughly $735 million from $41 million a year earlier. Under returning CEO Stephen Hemsley, the company has emphasized profitability over enrollment growth, a move that has improved sentiment and supported a substantial rebound from 2025 lows.
The companies differ most clearly in scale and structure. UnitedHealth is roughly four times Elevance’s market capitalization and operates a larger, more integrated services engine through Optum. Elevance, by contrast, maintains a more balanced mix across commercial and government lines and leans heavily on Carelon for diversification. In growth drivers, Elevance is focused on margin expansion and Carelon cross-selling, while UnitedHealth is consolidating after a deliberate pullback from lower-margin business.
On recent momentum, UnitedHealth has posted the more dramatic recovery, rising substantially from its early-2026 trough as margin repair took hold. Elevance has been comparatively steadier, with gains linked to consistent earnings execution rather than a rebound narrative. Risk factors also vary in emphasis: Elevance carries notable Medicaid and state-rate sensitivity, whereas UnitedHealth faces the largest Medicare Advantage footprint and ongoing regulatory scrutiny. Valuation and dividend profiles differ as well, with UnitedHealth offering a higher yield and Elevance a lower payout ratio, reflecting distinct capital-return approaches. From what I see, these distinctions matter when weighing relative risk and reward.
Based on observable trend consistency, stability, and relative positioning, Tickeron’s AI would likely favor UnitedHealth Group at present, given its stronger established uptrend, improving margin trajectory, and clearer earnings-recovery catalysts across its insurance and Optum segments. Elevance Health remains a solid, well-diversified candidate with attractive long-term fundamentals, but its momentum has been less decisive and its recent beat partly reflected non-operating items. This assessment is probabilistic rather than definitive: both names carry exposure to medical-cost trends and policy risk, and relative positioning could shift as new data emerges. Traders and investors should weigh trend strength against valuation and their own objectives. I’m watching this closely for any signs of convergence or further divergence.
I’ve found that reviewing Tickeron’s Trending AI Robots page provides a useful snapshot of top-performing automated strategies across thousands of tickers. The platform hosts hundreds of AI trading bots, each with its own style, timeframe, performance record, and set of covered securities. Because market conditions shift, only the bots best suited to the current environment appear in the curated rankings. Checking these regularly helps identify approaches aligned with prevailing momentum and volatility.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of hospital and medical service plans
Industry ManagedHealthCare